Testing a new imaging agent for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new radioactive tracer called ⁶⁸Ga-FC516 to see how well it works for imaging prostate cancer. It may help doctors find and monitor prostate cancer more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be either a healthy volunteer or a patient with confirmed prostate cancer.
- If you have prostate cancer, it must be confirmed by a biopsy or other cell analysis.
- You must not have severe liver, kidney, or heart problems.
- You must not be severely obese or have conditions that make a PET/CT scan difficult.
- You must not have allergies to any ingredient in the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study tests a new imaging scan (called 68Ga-OncoACP3-PET/CT) to help find prostate cancer and see where it may have spread. The scan uses a radioactive tracer to help doctors visualize cancer cells and decide on the best treatment options.
This trial compares two types of PET scans—one using a new tracer called [18F]F-PSMA-N5 and another using an existing tracer called [68Ga]Ga-PSMA-11—to see which is better at finding prostate cancer, including early signs of recurrence. If you have or are suspected of having prostate cancer, this study may help determine how advanced the disease is.
This trial tests a new radioactive tracer called ELI421 to see how well it works for PET imaging in people with prostate cancer. It may help doctors find cancer more clearly.
This study uses two different PSMA PET/CT tracers to see how well they detect cancer in patients with advanced prostate cancer that has spread or stopped responding to hormone therapy. The goal is to improve imaging for better treatment decisions.
This study tests a new type of imaging scan called 68Ga-FAPI-PSMA PET that may help doctors better detect and diagnose solid tumors like prostate, liver, ovarian, or endometrial cancer. You would receive the scan before having a biopsy or surgery.
This trial uses special PET imaging to see where progressive prostate cancer is in the body—one tracer to look at general sugar use and one designed to detect testosterone-related activity. It may help doctors better map cancer spread so future treatment planning can be more targeted.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.